Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6PKH6

UPID:
DR4L2_HUMAN

ALTERNATIVE NAMES:
Short chain dehydrogenase/reductase family 25C member 3

ALTERNATIVE UPACC:
Q6PKH6; H0YN69; Q3YLD4

BACKGROUND:
The protein Dehydrogenase/reductase SDR family member 4-like 2, alternatively known as Short chain dehydrogenase/reductase family 25C member 3, functions as a probable oxidoreductase. It is integral to various biochemical pathways, facilitating essential oxidation-reduction reactions that support the organism's metabolic balance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dehydrogenase/reductase SDR family member 4-like 2 is crucial for identifying novel therapeutic approaches. Its critical role in metabolism and detoxification processes makes it a promising candidate for the development of drugs aimed at regulating its activity for disease treatment and prevention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.